Waters Highlights Investor Update and Spin-Off Transaction Progress
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Waters ( (WAT) ) has shared an update.
Waters Corporation plans to present an investor presentation at the J.P. Morgan Healthcare Conference on January 12, 2026, where President and CEO Udit Batra will provide high-level commentary on the company’s business performance, with a transcript to be made available on its website afterward. The company also detailed the progress of its proposed transaction with Becton, Dickinson and Company and Augusta SpinCo Corporation, noting that the SEC declared effective Waters’ Form S-4 registration statement and SpinCo’s Form 10 on December 23 and December 31, 2025, respectively, and that a definitive proxy statement/prospectus was mailed to Waters shareholders of record as of December 19, 2025, signaling an advanced stage in the regulatory and shareholder communication process for the deal.
The most recent analyst rating on (WAT) stock is a Hold with a $400.00 price target. To see the full list of analyst forecasts on Waters stock, see the WAT Stock Forecast page.
Spark’s Take on WAT Stock
According to Spark, TipRanks’ AI Analyst, WAT is a Outperform.
Waters Corporation’s strong earnings call and financial performance are the most significant factors driving the stock score. The technical analysis and valuation suggest caution due to potential overvaluation and overbought conditions. The company’s strategic initiatives and raised guidance provide a positive outlook, but cash flow management remains an area for improvement.
To see Spark’s full report on WAT stock, click here.
More about Waters
Waters Corporation is a life sciences and analytical instruments company that provides laboratory technologies, including chromatography, mass spectrometry and related analytical systems, primarily serving pharmaceutical, biopharmaceutical, healthcare and industrial customers worldwide, with a strong focus on regulated and research markets.
Average Trading Volume: 578,069
Technical Sentiment Signal: Buy
Current Market Cap: $23.62B
For a thorough assessment of WAT stock, go to TipRanks’ Stock Analysis page.
